PHP
ASND icon

Parkman Healthcare Partners’s Ascendis Pharma A/S ASND Stock Holding History

Parkman Healthcare Partners’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,343
Closed -$8.02M – 102
2025
Q3 		$8.02M Sell
40,343
-1,765
-4% -$329K 0.84% 44
2025
Q2 		$7.27M Buy
+42,108
New +$6.86M 0.84% 46
2020
Q1 		– Sell
-23,004
Closed -$3.2M – 67
2019
Q4 		$3.2M Buy
+23,004
New +$2.56M 0.92% 36

Other funds holding ASND

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Parkman Healthcare Partners's ASND Position: Q4 2025 in Review

Parkman Healthcare Partners sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 40,343 shares — an estimated $8.02M sold.

Parkman Healthcare Partners first reported a position in ASND in Q4 2019 and held it in 3 quarters. The position peaked at $8.02M in Q3 2025. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

  • Parkman Healthcare Partners reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
  • Parkman Healthcare Partners sold 40,343 Ascendis Pharma A/S shares in Q4 2025, an estimated $8.02M.
  • Parkman Healthcare Partners first reported a position in Ascendis Pharma A/S in Q4 2019 and held it in 3 quarters.
  • Parkman Healthcare Partners's Ascendis Pharma A/S position peaked at $8.02M in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Parkman Healthcare Partners's 13F filing for Q4 2025, filed 17 Feb 2026.